Several proven alternatives to colonoscopy can detect colon cancer, ranging from simple at-home stool tests to imaging scans and even a blood draw. None are quite as thorough as a traditional colonoscopy for finding precancerous polyps, but they catch the majority of actual cancers and can be a practical option if you want to avoid sedation, prep, or an invasive procedure. Screening is recommended starting at age 45 for people at average risk.
Stool Tests You Can Do at Home
The simplest alternatives are stool-based tests, which you collect at home and mail to a lab. There are three main types, and they differ in what they detect and how often you need to repeat them.
Fecal Immunochemical Test (FIT)
FIT looks for tiny amounts of human blood in your stool, which can signal a tumor or large polyp. It detects colorectal cancer about 80% of the time with a single use. Its main limitation is catching precancerous growths: sensitivity for advanced adenomas (the polyps most likely to become cancer) is only 20% to 30%. That’s why FIT is designed to be repeated every year. Over several years of annual testing, your cumulative odds of catching something serious improve substantially.
FIT has no dietary restrictions. You collect a small sample at home, seal it in the provided kit, and send it to a lab. Results typically come back within a couple of weeks. If your result is positive, it doesn’t necessarily mean cancer. In a large CDC-analyzed study, only about 3% of people with a positive FIT turned out to have colorectal cancer, while roughly 21% had an advanced adenoma. The rest had smaller polyps or no significant findings. A positive result does mean you’ll need a follow-up colonoscopy to find out what’s going on.
Multi-Target Stool DNA Test (Cologuard)
This test combines a FIT with DNA analysis that looks for genetic mutations shed by cancerous or precancerous cells. It catches colorectal cancer 92% of the time, a meaningful improvement over FIT alone. However, it detects advanced adenomas only about 42% of the time, so it still misses more than half of precancerous polyps. It’s recommended every one to three years rather than annually.
The collection process is slightly more involved than FIT. You provide an entire stool sample in a special container, add a preservative, and ship it to the lab. A positive result still requires a colonoscopy for confirmation. False positives are more common than with FIT, which means some people will go through a colonoscopy that turns up nothing.
Guaiac-Based Fecal Occult Blood Test (gFOBT)
This older test also detects blood in stool, but it uses a chemical reaction rather than antibodies. It’s less accurate than FIT and comes with dietary restrictions that start three days before you begin collecting samples. You’ll need to avoid red meat, raw fruits and vegetables, vitamin C supplements above 250 mg per day, antacids, and iron supplements. Most people also need to stop taking aspirin, other anti-inflammatory pain relievers, and vitamin E during the collection period (though if you take aspirin for heart protection, check with your provider before stopping). These restrictions exist because certain foods and medications can trigger false positives or mask real bleeding. gFOBT is repeated annually, like FIT, but because FIT is simpler and more accurate, most screening programs have shifted to FIT.
Blood Tests for Colorectal Cancer
A blood draw is the least burdensome screening option available. The FDA approved a test called Shield in 2024, making it the first blood-based colorectal cancer screening test to receive clearance. In a clinical study of nearly 7,900 people, Shield detected colorectal cancer 83% of the time. About 1 in 10 people without advanced abnormal cells will get a false positive.
The tradeoff is that blood tests are weaker at finding precancerous polyps than stool tests or imaging. Shield is best thought of as a screening tool for people who would otherwise skip screening entirely. If the choice is between a blood test and no test at all, the blood test is a clear win. If you’re open to stool testing or imaging, those options catch more precancerous growths.
An older blood test called Epi proColon, which detects a specific DNA methylation marker, has been available for several years. Its sensitivity for cancer ranges from about 68% to 81% depending on the scoring method, which is lower than both Shield and stool-based options.
CT Colonography (Virtual Colonoscopy)
CT colonography uses a CT scanner to create detailed images of your colon and rectum. In the National CT Colonography Trial, it detected polyps 10 mm or larger in 90% of cases where colonoscopy confirmed them. That’s close to the accuracy of traditional colonoscopy for the polyps most likely to harbor cancer.
The catch is that virtual colonoscopy still requires bowel prep. You’ll follow a clear liquid diet the day before, take laxatives or enemas, drink a contrast liquid, and fast for several hours before the procedure. The prep is similar to what you’d do for a regular colonoscopy. The difference is the procedure itself: no sedation, no scope, and no recovery time. A small tube is placed in the rectum to inflate the colon with air, and then the scan takes about 10 to 15 minutes. You can go back to normal activities right after.
If the scan finds a polyp 6 mm or larger, you’ll still need a traditional colonoscopy to remove it. Since a virtual colonoscopy can’t remove polyps during the exam, some people end up doing two rounds of prep: one for the scan and one for the follow-up colonoscopy. For that reason, it’s generally recommended every five years and is most useful for people who can’t undergo sedation or have medical reasons to avoid an invasive procedure.
Capsule Endoscopy
Colon capsule endoscopy involves swallowing a pill-sized camera that takes thousands of images as it travels through your digestive tract. Across multiple large studies and meta-analyses, the second-generation capsule camera detects polyps 6 mm or larger with about 86% to 87% sensitivity, and polyps 10 mm or larger with roughly 87% to 88% sensitivity.
This option requires bowel prep, similar to a colonoscopy or CT scan, because the camera needs a clear view. It’s not yet widely available in the U.S. as a routine screening tool, though it’s used more commonly in parts of Europe. Like virtual colonoscopy, it can identify polyps but can’t remove them, so a positive finding leads to a follow-up colonoscopy.
How These Options Compare
- Best for convenience: FIT (once a year, no prep, no restrictions) or a blood test like Shield (single blood draw)
- Highest cancer detection without a scope: Multi-target stool DNA testing at 92% sensitivity for cancer
- Best for finding large polyps: CT colonography at 90% sensitivity for polyps 10 mm or larger
- Most similar to colonoscopy experience: Capsule endoscopy (still requires prep, still visual inspection of the colon)
Every non-colonoscopy option shares one important limitation: if something suspicious is found, you’ll need a colonoscopy anyway to confirm the diagnosis or remove a polyp. These alternatives are screening tools, not replacements for the diagnostic and therapeutic role of colonoscopy. Their real value is in catching problems early while being easier to say yes to, especially if repeated on schedule.
Choosing the Right Test for You
Your choice depends on what you’re most trying to avoid. If it’s the prep, stool tests and blood tests eliminate that entirely. If it’s sedation and the scope itself, CT colonography gives you imaging accuracy with a less invasive procedure (though you still prep). If cost or access is the barrier, FIT kits are inexpensive, widely covered by insurance, and available through most primary care offices.
The most important factor is actually doing the screening. A large proportion of colorectal cancers are found in people who were never screened at all. An imperfect test done consistently outperforms a perfect test that never happens. If a yearly FIT or a blood draw every three years is what you’ll actually follow through on, that’s a far better strategy than putting off a colonoscopy indefinitely.